New and Future Therapies
Atopic dermatitis (AD) is caused by a complex interrelationship of a variety of genetic and environmental factors, leading to the maintenance of the chronic inflammatory skin condition.
Most conventional treatments have been designed for the so-called average patient. However, because of recent advances in life science, a more precise diagnosis of individual patients can be made, and even among patients who have the same disease, detailed subgroup classification is presumably possible. The concept that treatment and prophylactic methods can be developed for each subgroup to deepen medical treatments is referred to as ‘precision medicine’.
In recent years, many previously unknown points concerning the mechanisms of the pathogenesis of AD have been elucidated, and novel treatments in line with the pathological mechanisms or based on subgroup classifications have been developed.
It is presumed that the re-establishment of medical care in the field of allergic diseases will also be based on the concept of ‘precision medicine’. Herein, we describe how future treatment strategies for atopic dermatitis can be developed on the basis of the idea of ‘precision medicine’.
KeywordsAtopic dermatitis Precision medicine Novel therapeutic approach Nucleic acid drugs
- 35.Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158:801–7.CrossRefPubMedGoogle Scholar
- 37.Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015; CD009864.Google Scholar
- 58.Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296–304.CrossRefPubMedGoogle Scholar